drugset / Trial / NCT07574060

Allopurinol in Depression

NCT07574060

Phase 2/3 Not yet recruiting 70 enrolled Tanta University
RandomizedParallel-groupDouble-blindTreatment

Summary

Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients.

Timeline

Start
2026-05-20
Primary completion
2027-05-20
Completion
2027-05-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule 300 mg
Comparator Sertraline Small molecule 50 mg